Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| These benefits will drive further adoption of ALLY as well as increased utilization as surgeons' comfort levels continue to grow and they see firsthand the value that our platform can create within their practice |
| And so it's allowing me to leverage and leverage myself a lot better there, and he's doing a really nice job |
| I'm excited to share with you both our achievements of the past 12 months, as well as some of the numerous reasons we're so excited for the future |
| We're approaching a perfect storm, combining an industry that has been ripe for innovation, which we're addressing through our world-class technology, the anticipation of an expanded geographic footprint to new regulatory clearances and improving market global market conditions |
| I can safely say that since launching in the mid-third quarter of 2022, ALLY has exceeded our expectations |
| We're really excited about the year ahead |
| Our distributors are well equipped and excited to make ALLY available to European surgeons quickly once we receive marketing authorization |
| I believe we're well positioned to translate these favorable dynamics into significant growth in the years to come |
| And primarily, we've had a phenomenal presence and a market share in Germany |
| Once again, this growth percentage is even more impressive if you consider the fact that we're currently limited to installing ALLYs in the US |
| Accordingly, our US installed base grew over 23%, a strong performance in any event |
| Importantly, demand for the technology remains strong as we finish 2023 with a backlog of nine systems and a robust pipeline of potential ALLY customers that we are diligently working to convert in the year ahead |
| In addition to this strong growth in our installed base, we continue to report highly encouraging utilization trends, with full year procedure volume up 4% over 2022 and fourth quarter procedures increasing nearly 20% compared to the year ago period |
| We were extremely pleased with our 19% revenue growth for the year based upon two limitations that we faced and will continue to face in 2024 |
| We have a clear set of objectives focused on maximizing the success of ALLY, and I'm proud to say that we are well on our way to making our vision a reality |
| Specifically, we now have four peer review papers demonstrating the superiority of LENSAR's proprietary astigmatic guiding technology IntelliAxis that enable surgeons to create astigmatic incisions and guide toric IOL alignment and deliver better outcomes to their patients |
| As Tom will review in greater detail, fourth quarter revenue grew 18% compared to a year ago, while full year revenue increased 19% in 2023 compared to 2022, also marking our highest annual revenue in the company's history |
| I'm confident that the significant momentum built throughout the year will continue in 2024 |
| Similar to the revenue story, our full year procedure growth becomes even more impressive when you exclude the effect of South Korea, which has essentially been shut down since mid-'22 |
| This makes ALLY a very compelling value proposition, providing a solid return on investment and alternative to the big company bundles |
| As you can see, independent data is beginning to emerge in support of our long-standing belief that ALLY offers a better device and overall technology solution to optimize the cataract surgical experience for surgeons, staff and patients |
| While the growth we've delivered over the last year is exciting on its own, looking at it in the context of the broader sector tells a similarly promising story |
| 2023 was by all measures a very strong year for our company |
| This marks our seventh consecutive quarter of gains in our primary geography and representing a 2.8% gain in market share since launching ALLY in the US Additionally, there is a significant number of competitive systems currently in use that are based on data technology and approaching end of life |
| The fourth quarter was a strong quarter for us, with revenue increasing $1.9 million or 18% from the fourth quarter of 2022 |
| The benefits of femtosecond laser-assisted cataract surgery are contributing to a higher annual growth rate expected to be between 5% and 8% |
| This data, combined with the benefit surgeons, staff and patients recognized with ALLY provides strong support for our expectation that LENSAR has the potential to achieve 20% plus year-over-year growth for the foreseeable future |
| Our growth to date and this anticipated growth are fueled not only by ALLY's efficiencies and business opportunities as previously outlined, but also the significant clinical contribution ALLY is making for surgeons and their patients |
| We continue to demonstrate with our customers the benefits ALLY offers, primarily with the significant speed, performance, the stigmatism management, and overall ergonomic efficiency compared to legacy technologies |
| And I expect that the numbers of procedures that we're doing despite headwinds macroeconomically for people here in the US that we're going to continue to see procedure numbers grow and grow within some of the commentary that we made during the call |
| Statement |
|---|
| And two, our revenue growth was into a strong headwind in South Korea, whereby premium cataract procedures have been virtually non-existent for the last 18 months due to third-party payor reimbursement issues |
| And you've seen that in 2024 or 2023, just with the amount of systems we were able to sell in a very, very difficult macro environment for capital equipment purchases |
| And so to Tom's comment, the more systems we sell has a drag on gross margins initially |
| Our margins decreased in the latter half of 2023 associated with a higher proportion of total revenue from system sales, which have a significantly lower gross margin than procedure sales as well as the roll-off of inventory charged to research and development prior to ALLY receiving regulatory clearance in the United States |
| Like we knew that some of them would contain some of the content, but some were actually big surprises |
| We've I don't think that as a whole, we couldn't be more enthusiastic in terms of the sort of momentum that we're trying -- that we're picking up and that we continue to sustain |
| So curious about that |
| Some unexpected by LENSAR in the commentary there |
| So as we get into 2024, I'm a little reticent to give too much too soon here |
| So I don't think -- and as we continue to grow, obviously, those percentages of revenue that were as high as 14.9% for LENSAR are going to be less significant, particularly if that market comes back to 50% of what it was |
Please consider a small donation if you think this website provides you with relevant information